Cover Image
市場調查報告書

黑素瘤(melanoma)治療藥市場:患者數的增加和治療流程的演進,推動市場成長

Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth

出版商 GBI Research 商品編碼 318233
出版日期 內容資訊 英文 189 Pages
訂單完成後即時交付
價格
Back to Top
黑素瘤(melanoma)治療藥市場:患者數的增加和治療流程的演進,推動市場成長 Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
出版日期: 2014年09月30日 內容資訊: 英文 189 Pages
簡介

黑素瘤(melanoma)治療藥市場,預測將從2013年的13億美元,以CAGR15.4%的速度成長到2020年將達到36億美元的規模。

本報告提供主要先進國家市場的黑素瘤(melanoma)治療藥市場相關調查分析,提供您市場概要,上市產品,開發中產品,市場預測,交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 黑色素瘤的種類
  • 症狀
  • 病因和危險因素
  • 黑色素瘤的分期
  • 診斷
  • 預後
  • 治療的選項
  • 治療流程
  • 治療區分

第3章 上市產品

  • 概要
  • 輔助性治療
  • 進行性黑色素瘤的治療
  • 上市產品的熱圖

第4章 黑色素瘤治療藥的開發平台

  • 概要
  • 開發平台分佈:各開發階段,各分子類型,各給藥途徑,新穎性
  • 開發平台分佈:分子標的別
  • 臨床試驗狀況
  • 有前途的開發平台分子
  • 開發中產品的熱圖與競爭企業矩陣

第5章 市場預測

  • 各地區市場
  • 全球市場
  • 北美
  • EU主要5個國家
  • 日本
  • 推動因素與阻礙

第6章 交易與策略性整合

  • 概要
  • 主要的共同開發交易
  • 主要的許可證交易

第7章 附錄

圖表

目錄
Product Code: GBIHC345MR

Summary

GBI Research, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth"

Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas.

Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.

Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for melanoma.The report covers and includes -

  • An introduction to the melanoma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diagnosis and treatment.
  • In-depth analysis of the current melanoma marketed products landscape including product profiles of the main drugs used in melanoma and heat maps that compare safety and efficacy parameters of the various drugs.
  • Comprehensive analysis of the melanoma pipeline by phase of development, molecule type, molecular target and novelty. A comparative analysis of late-stage pipeline drugs that are likely to enter the market in the forecast period is also provided alongside heat maps.
  • Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates and primary and secondary endpoints.
  • Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new drugs and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
  • Discussion of the licensing and co-development strategic consolidations landscape in melanoma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals.

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to

  • Gain a comprehensive understanding of the melanoma indication including segmentation of disease and treatment algorithms.
  • Understand the current melanoma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved.
  • Identify trends and developments within the melanoma pipeline including which molecule types and molecular targets are prominent.
  • Consider market opportunities and potential risks by examining trends in melanoma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the melanoma therapeutics market.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Types of Melanoma
  • 2.3. Symptoms
    • 2.3.1. Cutaneous Melanoma
    • 2.3.2. Ocular Melanoma
    • 2.3.3. Mucosal Melanomas
    • 2.3.4. Melanomas of the Internal Organs and Soft Parts
    • 2.3.5. Advanced Melanoma
  • 2.4. Etiology and Risk Factors
    • 2.4.1. Phenotypic Characteristics
    • 2.4.2. Exposure to Ultraviolet Radiation
    • 2.4.3. Personal or Family History of Melanoma
    • 2.4.4. Xeroderma Pigmentosum
    • 2.4.5. Parkinson's Disease
  • 2.5. Pathophysiology
    • 2.5.1. Cutaneous Melanoma
    • 2.5.2. Ocular Melanoma
    • 2.5.3. Mucosal Melanoma
    • 2.5.4. Underlying Molecular Pathways
  • 2.6. Melanoma Staging
  • 2.7. Diagnosis
    • 2.7.1. Cutaneous Melanoma
    • 2.7.2. Ocular Melanoma
    • 2.7.3. Mucosal Melanoma
  • 2.8. Epidemiology
    • 2.8.1. Cutaneous Melanoma
    • 2.8.2. Ocular Melanoma
    • 2.8.3. Mucosal Melanoma
  • 2.9. Treatment Options
    • 2.9.1. Surgery
    • 2.9.2. Radiation Therapy
    • 2.9.3. Pharmacotherapy
  • 2.10. Treatment Algorithms
    • 2.10.1. Cutaneous Melanoma
    • 2.10.2. Ocular Melanoma
    • 2.10.3. Mucosal Melanoma
  • 2.11. Treatment Segments
    • 2.11.1. Adjuvant Therapy for CM (All Mutations)
    • 2.11.2. Advanced Therapy for CM (All Mutations)
    • 2.11.3. Advanced Therapy for CM (BRAF Mutated Patients Only)

3. Marketed Products

  • 3.1. Overview
  • 3.2. Adjuvant therapy
    • 3.2.1. Immunotherapy
  • 3.3. Therapy for Advanced (Unresectable or Metastatic) Melanoma
    • 3.3.1. Chemotherapy
    • 3.3.2. Immunotherapy
    • 3.3.3. Targeted Therapies
  • 3.4. Heat Maps for Marketed Products

4. Melanoma Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
  • 4.3. Pipeline Distribution by Molecular Target
  • 4.4. Clinical Trial Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Primary and Secondary Endpoints
  • 4.5. Promising Pipeline Molecules
    • 4.5.1. Adjuvant Immunotherapy
    • 4.5.2. Advanced Disease Immunotherapy
    • 4.5.3. Advanced Disease Targeted Therapy
  • 4.6. Heat Map and Competitor Matrix for Pipeline Products

5. Market Forecast to 2020

  • 5.1. Geographical Markets
  • 5.2. Global Market
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Top Five EU Markets
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Driver and Barriers for the Melanoma Therapeutics Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Strategic Consolidations

  • 6.1. Overview
  • 6.2. Co-development Deals
    • 6.2.1. GlaxoSmithKline Enters into Co-development Agreement with Synta Pharma for elesclomol (STA-4783) - Deal Now Terminated
    • 6.2.2. Exelixis Enters into Co-development Agreement with Genentech for cobimetinib
    • 6.2.3. Roche Enters into Co-development Agreement with Bristol-Myers Squibb for Zelboraf/Yervoy Combination Drug - No Longer Under Development for Melanoma
  • 6.3. Licensing Deals
    • 6.3.1. Chugai Pharma Enters into Licensing Agreement with Roche for Zelboraf
    • 6.3.2. Colby Enters into Licensing Agreement with MannKind for Cancer Immunotherapy Products - No Longer Under Development for Melanoma
    • 6.3.3. Molecular Insight Enters into Licensing Agreement with Bayer Schering Pharma for Solazed - No Longer Under Development for Melanoma - No Longer Under Development for Melanoma

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. 2.2.6 Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. References
    • 7.3.1. References for Heat Maps
  • 7.4. Abbreviations
  • 7.5. Research Methodology
    • 7.5.1. Secondary Research
    • 7.5.2. Marketed Product Profiles
    • 7.5.3. Late-Stage Pipeline Candidates
    • 7.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.5.5. Product Competitiveness Framework
    • 7.5.6. Pipeline Analysis
    • 7.5.7. Forecasting Model
    • 7.5.8. Deals Data Analysis
  • 7.6. Contact Us
  • 7.7. Disclaimer

List of Tables

  • Table 1: Characteristics of Types of Melanoma
  • Table 2: Staging of Cutaneous Melanoma
  • Table 3: Melanoma Clinical Trial Endpoint Definitions
  • Table 4: Melanoma Therapeutics Market, Global, Pipeline, Groups of Molecular Targets, 2014
  • Table 5: Breakdown of 'Other' Molecular Targets
  • Table 6: Breakdown of Molecular Target Combinations
  • Table 7: Melanoma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2014
  • Table 8: Melanoma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
  • Table 9: Melanoma Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2014
  • Table 10: Melanoma Therapeutics, Global, All Pipeline Products, Phase I, 2014
  • Table 11: Melanoma Therapeutics, Global, All Pipeline Products, Phase II, 2014
  • Table 12: Melanoma Therapeutics, Global, All Pipeline Products, Phase III, 2014
  • Table 13: Melanoma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2014
  • Table 14: Melanoma Therapeutics Market, Global, Market Forecast, 2013-2020
  • Table 15: Melanoma Therapeutics Market, US, Market Forecast, 2013-2020
  • Table 16: Melanoma Therapeutics Market, Canada, Market Forecast, 2013-2020
  • Table 17: Melanoma Therapeutics Market, UK, Market Forecast, 2013-2020
  • Table 18: Melanoma Therapeutics Market, France, Market Forecast, 2013-2020
  • Table 19: Melanoma Therapeutics Market, Germany, Market Forecast, 2013-2020
  • Table 20: Melanoma Therapeutics Market, Italy, Market Forecast, 2013-2020
  • Table 21: Melanoma Therapeutics Market, Spain, Market Forecast, 2013-2020
  • Table 22: Melanoma Therapeutics Market, Japan, Market Forecast, 2013-2020
  • Table 23: List of Abbreviations

List of Figures

  • Figure 1: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Marketed Products, 2014
  • Figure 2: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014
  • Figure 3: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014 (continued)
  • Figure 4: Melanoma Therapeutics Market, Global, Pipeline, 2014
  • Figure 5: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Biologics and Gene/Cell Therapies, 2014
  • Figure 6: Melanoma Therapeutics Market, Global, Pipeline, Repositioned Molecules by Original Indication, 2014
  • Figure 7: Melanoma Therapeutics Market, Global, Pipeline by Molecular Target, 2014
  • Figure 8: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Protein Kinase Molecular Targets by Phase of Development, 2014
  • Figure 9: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Antigens/Antigen Ligands Molecular Targets by Phase of Development, 2014
  • Figure 10: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Cytokine/Cytokine Receptor Molecular Targets by Phase of Development, 2014
  • Figure 11: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates by Phase of Development and Overall Clinical Trial Attrition Rate, 2006-2013 (%)
  • Figure 12: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical Trial Attrition Rate by Molecule Type (%), 2006-2013
  • Figure 13: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical Trial Attrition Rate by Molecular Target (%), 2006-2013
  • Figure 14: Melanoma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type (months), 2006-2013
  • Figure 15: Melanoma Therapeutics Market, Global, Clinical Trial Size by Molecule Type (participants), 2006-2013
  • Figure 16: Melanoma Therapeutics Market, Global, Failure Rate, Average Trial Duration and Average Trial Recruitment Size by Molecule Type, 2006-2013
  • Figure 17: Melanoma Therapeutics Market, Global, Pipeline, Primary Clinical Trial Endpoints by Phase of Development (%), 2006-2013
  • Figure 18: Melanoma Therapeutics Market, Global, Breakdown of Safety/drug Biochemistry and Efficacy Clinical Trial Primary Endpoints by Phase of Development, 2006-2013
  • Figure 19: Melanoma Therapeutics Market, Global, Secondary Clinical Trial Endpoints by Phase of Development (%), 2006-2013
  • Figure 20: Melanoma Therapeutics Market, Global, Breakdown of Safety/drug biochemistry, Efficacy and 'Other' Clinical Trial Secondary Endpoints by Phase of Development, 2006-2013
  • Figure 21: Melanoma Therapeutics Market, Global Sales Forecast for Seviprotimut-L ($m), 2017-2020
  • Figure 22: Melanoma Therapeutics Market, Global, Sales Forecast for Yervoy (Adjuvant Setting) ($m), 2016-2020
  • Figure 23: Melanoma Therapeutics Market, Global Sales Forecast for Talimogene Laherparepvec (T-Vec) ($m), 2015-2020
  • Figure 24: Melanoma Therapeutics Market, Global, Sales Forecast for Selumetinib ($m), 2016-2020
  • Figure 25: Melanoma Therapeutics Market, Global Sales Forecast for Binimetinib ($m), 2016-2020
  • Figure 26: Melanoma Therapeutics Market, Global, Sales Forecast for Cobimetinib ($m), 2015-2020
  • Figure 27: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Pipeline Products, 2014
  • Figure 28: Melanoma Therapeutics Market, Global, Heat Map for Advanced Pipeline Products, 2014
  • Figure 29: Melanoma Therapeutics Market, Global, Heat Map for Advanced Pipeline Products, 2014 (continued)
  • Figure 30: Melanoma Therapeutics Market, Global, Competitor Matrix for Advanced Products, 2014
  • Figure 31: Melanoma Therapeutics Market, Global, Treatment Patterns ('000) and Market Size ($bn), 2013-2020
  • Figure 32: Melanoma Therapeutics Market, North America, Treatment Patterns, 2013-2020
  • Figure 33: Melanoma Therapeutics Market, North America, Annual Cost of Therapy ($), 2013-2020
  • Figure 34: Melanoma Therapeutics Market, North America, Market Size, 2013-2020
  • Figure 35: Melanoma Therapeutics Market, Five EU Countries, Treatment Patterns ('000), 2013-2020
  • Figure 36: Melanoma Therapeutics Market, Top Five EU Countries, Annual Cost of Therapy ($), 2013-2020
  • Figure 37: Melanoma Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013-2020
  • Figure 38: Melanoma Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2013-2020
  • Figure 39: Melanoma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 40: Melanoma Therapeutics Market, Japan, Market Size ($m), 2013-2020
  • Figure 41: Melanoma Therapeutics Market, Global, Co-development Deals by Region, 2006-2014
  • Figure 42: Melanoma Therapeutics Market, Global, Co-development Deals by Deal Value, 2006-2014
  • Figure 43: Melanoma Therapeutics Market, Global, Co-development Deals by Year, 2006-2014
  • Figure 44: Melanoma Therapeutics Market, Global, Co-development Deals by Phase of Development, Deal Value and Upfront Payment ($m), 2006-2014
  • Figure 45: Melanoma Therapeutics Market, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006-2014
  • Figure 46: Melanoma Therapeutics Market, Global, Licensing Deals by Region, 2006-2014
  • Figure 47: Melanoma Therapeutics Market, Global, Licensing Deals by Deal Value, 2006-2014
  • Figure 48: Melanoma Therapeutics Market, Global, Licensing Deals by Year, 2006-2014
  • Figure 49: Melanoma Therapeutics Market, Global, Licensing Deals by Phase of Development, Deal Value and Upfront Payment ($m), 2006-2014
  • Figure 50: Melanoma Therapeutics Market, Licensing Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006-2014
Back to Top